Please use this identifier to cite or link to this item:
https://ir.swu.ac.th/jspui/handle/123456789/15188
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Srisawat S. | |
dc.contributor.author | Phivthong-Ngam L. | |
dc.contributor.author | Unchern S. | |
dc.contributor.author | Chantharaksri U. | |
dc.contributor.author | Govitrapong P. | |
dc.contributor.author | Sanvarinda Y. | |
dc.date.accessioned | 2021-04-05T04:32:54Z | - |
dc.date.available | 2021-04-05T04:32:54Z | - |
dc.date.issued | 2003 | |
dc.identifier.issn | 3051870 | |
dc.identifier.other | 2-s2.0-0038809114 | |
dc.identifier.uri | https://ir.swu.ac.th/jspui/handle/123456789/15188 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-0038809114&doi=10.1046%2fj.1440-1681.2003.03850.x&partnerID=40&md5=614cdd7a0c2f6603f71cc13dfb8bbbf5 | |
dc.description.abstract | 1. Atherosclerotic cardio- and cerebrovascular disease is a leading cause of mortality in Western countries. Aspirin-like drugs are widely used to prevent and treat these occlusive cardio- and cerebrovascular diseases. The beneficial effects of these drugs have been largely attributed to inhibition of platelet cyclo-oxygenase activity and thromboxane (TX) A2 production. We investigated the effect of an aspirin-like drug, namely indomethacin, on endothelial function, plaque and platelet aggregation and the formation of vasoactive substances during the development of atherosclerosis in cholesterol-fed rabbits. 2. Rabbits were fed 1% cholesterol (n = 8), 1% cholesterol plus 25 mg/day indomethacin (n = 8) or normal rabbit chow (control group; n = 8) for 12 weeks. Urinary excretion rates of 2,3-dinor-TXB2, 6-keto-prostaglandin (PG) F1α, 8-iso-PGF2α, and nitrate were analysed at the beginning of dietary intervention and at 4 weekly intervals thereafter. At the end of the study period, platelet aggregation, aortic plaque formation and endothelium-dependent and -independent vascular functions of isolated aortic rings ex vivo were assessed. 3. Compared with control, in the cholesterol-fed group, urinary 2,3-dinor-TXB2, 6-keto-PGF1α and 8-iso-PGF2α excretion and platelet aggregation were significantly increased (P < 0.05), but urinary excretion of nitrate was decreased (P < 0.05). Treatment with indomethacin significantly reduced platelet aggregation, urinary 2,3-dinor-TXB2, 6-keto-PGF1α, and 8-iso-PGF2α excretion (P < 0.05 vs the cholesterol-fed group) and attenuated the reduction in urinary nitrate excretion. 4. Cholesterol feeding progressively increased aortic intimal thickening and impaired endothelium-dependent vasodilator function (P < 0.05 vs control), whereas indomethacin partially prevented aortic plaque formation and restored endothelium-dependent vasodilation (P < 0.05 vs the cholesterol-fed group). 5. The present study demonstrates that indomethacin reduces the progression of atherosclerotic lesions and improves endothelium-mediated vascular responses ex vivo in cholesterol-fed rabbits. The beneficial effects of indomethacin may be due to its ability to prevent the elevation of platelet aggregation, TXA2 (measured as urinary 2,3-dinor-TXB2 excretion) and 8-iso-PGF2α, formation and to retard the decrease in endogenous nitric oxide synthesis (assessed as urinary excretion of nitrate). Despite indomethacin treatment leading to the suppression of prostacyclin biosynthesis (assessed as urinary 6-keto-PGF1α excretion), according to our data, indomethacin appears to preserve endothelial function. | |
dc.subject | 2,3 dinorthromboxane B2 | |
dc.subject | 6 oxoprostaglandin F1 alpha | |
dc.subject | 8 isoprostaglandin F2 alpha | |
dc.subject | acetylsalicylic acid | |
dc.subject | cholesterol | |
dc.subject | indometacin | |
dc.subject | nitrate | |
dc.subject | nitric oxide | |
dc.subject | prostacyclin | |
dc.subject | prostaglandin synthase inhibitor | |
dc.subject | thromboxane A2 | |
dc.subject | animal cell | |
dc.subject | animal model | |
dc.subject | animal tissue | |
dc.subject | artery intima proliferation | |
dc.subject | article | |
dc.subject | atherosclerosis | |
dc.subject | atherosclerotic plaque | |
dc.subject | blood vessel function | |
dc.subject | cerebrovascular disease | |
dc.subject | controlled study | |
dc.subject | coronary artery atherosclerosis | |
dc.subject | diet | |
dc.subject | endothelium | |
dc.subject | male | |
dc.subject | mortality | |
dc.subject | nonhuman | |
dc.subject | rabbit | |
dc.subject | thrombocyte aggregation | |
dc.subject | urinary excretion | |
dc.subject | Animals | |
dc.subject | Aorta, Thoracic | |
dc.subject | Arteriosclerosis | |
dc.subject | Cholesterol, Dietary | |
dc.subject | Cyclooxygenase Inhibitors | |
dc.subject | Endothelium, Vascular | |
dc.subject | Male | |
dc.subject | Rabbits | |
dc.subject | Vasodilation | |
dc.title | Improvement of vascular function by chronic administration of a cyclo-oxygenase inhibitor in cholesterol-fed rabbits | |
dc.type | Article | |
dc.rights.holder | Scopus | |
dc.identifier.bibliograpycitation | Clinical and Experimental Pharmacology and Physiology. Vol 30, (2003), p.405-412 | |
dc.identifier.doi | 10.1046/j.1440-1681.2003.03850.x | |
Appears in Collections: | Scopus 1983-2021 |
Files in This Item:
There are no files associated with this item.
Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.